Protein phosphatase 1 alpha enhances glucocorticoid receptor activity by a mechanism involving phosphorylation of serine-211 by Patt, Melanie et al.
Contents lists available at ScienceDirect
Molecular and Cellular Endocrinology
journal homepage: www.elsevier.com/locate/mce
Protein phosphatase 1 alpha enhances glucocorticoid receptor activity by a
mechanism involving phosphorylation of serine-211
Melanie Patta,b, Joël Gysib, Nourdine Faressec, John A. Cidlowskid, Alex Odermatta,b,∗
a Swiss Centre for Applied Human Toxicology (SCAHT), University of Basel, Missionsstrasse 64, 4055, Basel, Switzerland
bDivision of Molecular and Systems Toxicology, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
c DIVA Expertise, 31100, Toulouse, France
d Signal Transduction Laboratory, NIEHS, National Institutes of Health, Department of Health and Human Services, Research Triangle Park, NC, 27709, USA
A R T I C L E I N F O
Keywords:
Glucocorticoid receptor
Protein phosphatase 1 alpha
Glycogen synthase kinase 3
Phosphorylation
Signaling
A B S T R A C T
By acting as a ligand-dependent transcription factor the glucocorticoid receptor (GR) mediates the actions of
glucocorticoids and regulates many physiological processes. An impaired regulation of glucocorticoid action has
been associated with numerous disorders. Thus, the elucidation of underlying signaling pathways is essential to
understand mechanisms of disrupted glucocorticoid function and contribution to diseases. This study found
increased GR transcriptional activity upon overexpression of protein phosphatase 1 alpha (PP1α) in HEK-
293 cells and decreased expression levels of GR-responsive genes following PP1α knockdown in the endogenous
A549 cell model. Mechanistic investigations revealed reduced phosphorylation of GR-Ser211 following PP1α
silencing and provided a first indication for an involvement of glycogen synthase kinase 3 (GSK-3). Thus, the
present study identified PP1α as a novel post-translational activator of GR signaling, suggesting that disruption
of PP1α function could lead to impaired glucocorticoid action and thereby contribute to diseases.
1. Introduction
Glucocorticoids (GC) are steroid hormones naturally produced and
secreted by the adrenal gland in order to maintain body homeostasis.
They act highly tissue-specifically and affect almost every organ in the
human body by regulating energy homeostasis (carbohydrates, lipids,
proteins), bone metabolism, cell growth and differentiation, apoptosis,
stress and immune responses, as well as brain function (Ahmad et al.,
2019; Blum and Maser, 2003; Buckingham, 2006; Garabedian et al.,
2017; Gross and Cidlowski, 2008; Quax et al., 2013). GC are essential
for life and dysregulation of their signaling is involved in numerous
disorders including metabolic and cardiovascular diseases, asthma and
chronic obstructive pulmonary disease (COPD), mood and cognitive
disorders, immune diseases and cancer. Because of their anti-in-
flammatory, immunosuppressive and pro-apoptotic effects, synthetic
GC are amongst the most widely prescribed drugs for the treatment of
inflammation, autoimmune disorders and cancer.
GC exert their effects by binding to the glucocorticoid receptor (GR),
a ligand-dependent transcription factor belonging to the nuclear re-
ceptor superfamily. The GR consists of an N-terminal transactivation
domain (NTD), a DNA binding domain (DBD) and a C-terminal ligand-
binding domain (LBD) (Zhou and Cidlowski, 2005). The NTD contains a
transcriptional activation function domain (AF-1) responsible for post-
translational modifications and protein-protein interactions. In the ab-
sence of ligand, the GR is sequestered in the cytoplasm in a heat-shock
protein 90 (HSP-90)-chaperone complex. Ligand binding induces con-
formational changes that allow the release of the cytosolic GR from the
HSP-90-chaperone complex, followed by receptor dimerization and
translocation into the nucleus. The hormone-activated GR binds then to
specific palindromic DNA sequences in the promoter regions of target
genes (glucocorticoid response elements, GREs) and regulates their
transcription. Induction or suppression of target gene transcription can
occur, depending on the cell type, promoter context and cofactor re-
cruitment. Upon prolonged exposure to GC, the GR is subjected to de-
gradation by the ubiquitin-proteasome pathway, resulting in termina-
tion of the transcriptional response (Connell et al., 2001; Galigniana
et al., 2004; Kinyamu and Archer, 2003; Sengupta and Wasylyk, 2001;
Wallace and Cidlowski, 2001; Wang and DeFranco, 2005; Webster
et al., 1997).
In addition to ligand binding, cross-talk with other signaling
https://doi.org/10.1016/j.mce.2020.110873
Received 22 November 2019; Received in revised form 17 April 2020; Accepted 18 May 2020
∗ Corresponding author. Swiss Centre for Applied Human Toxicology and Division of Molecular and Systems Toxicology, Department of Pharmaceutical Sciences,
University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland.
E-mail addresses: melanie.patt@unibas.ch (M. Patt), joel.gysi@gmx.ch (J. Gysi), nourdine.faresse@diva-expertise.com (N. Faresse),
cidlows1@niehs.nih.gov (J.A. Cidlowski), Alex.Odermatt@unibas.ch (A. Odermatt).
Molecular and Cellular Endocrinology 518 (2020) 110873
Available online 22 June 2020
0303-7207/ © 2020 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license 
(http://creativecommons.org/licenses/by/4.0/).
T
pathways can modulate GR activity by post-translational modifications,
including phosphorylation, ubiquitination, and SUMOylation (Faus and
Haendler, 2006; Garza et al., 2010; Ismaili and Garabedian, 2004; Le
Drean et al., 2002; Wallace and Cidlowski, 2001). GR phosphorylation
affects its interaction with co-regulators, subcellular localization, DNA
binding and protein stability. Phosphorylation is paramount in receptor
regulation and highly cell-, tissue-, species- and promoter-specific and
the vast diversity of kinases and phosphatases mediates the high variety
of cellular responses to GC (Galliher-Beckley and Cidlowski, 2009; Zhou
and Cidlowski, 2005). Various kinases, including cyclin-dependent ki-
nases (CDKs), p38 mitogen activated protein kinases (MAPKs), c-Jun N-
terminal kinases (JNKs), extracellular signal-regulated kinases (ERKs),
protein kinase B (Akt), and glycogen synthase kinase 3 (GSK-3) were
shown to modulate GR activity by phosphorylation at several sites,
including serine residues 134, 203, 211, 226 and 404 (DeFranco et al.,
1991; Galliher-Beckley et al., 2008, 2011; Habib et al., 2017; Itoh et al.,
2002; Kino et al., 2007; Krstic et al., 1997; Miller et al., 2005; Rogatsky
et al., 1998a,b; Webster et al., 1997).
GR function is regulated by numerous phosphatases. Recent studies
emphasized the importance of protein phosphatases in regulating GR
and contributing to the cytokine-induced GC insensitivity seen in pa-
tients with severe asthma (Bouazza et al., 2012; Kobayashi et al., 2011;
Pazdrak et al., 2016). Protein phosphatase 2A (PP2A) was found to
dephosphorylate JNK, resulting in decreased GR-Ser226 phosphoryla-
tion and enhanced GR nuclear translocation, while protein phosphatase
5 (PP5) was proposed to negatively regulate GR activity by direct de-
phosphorylation of GR-Ser211. Besides, PP2A was suggested to form a
trimeric complex with GR and the scaffold protein striatin-3 (Petta
et al., 2017). In the presence of striatin-3, PP2A might be recruited to
facilitate dephosphorylation of GR-Ser211, thereby resulting in dimin-
ished GR transcriptional activity.
Protein phosphatase 1 alpha (PP1α) has been shown to control the
expression and activity of several steroid receptors, including the mi-
neralocorticoid receptor (MR), the androgen receptor (AR) and the
estrogen receptor-α (ER) (Bollig et al., 2007; Liu et al., 2016; Nagarajan
et al., 2017). PP1α was found to bind to the LBD of these steroid re-
ceptors, thereby stabilizing their expression by dephosphorylation and
inactivation of the E3 ubiquitin-ligase mouse double minute 2 (MDM2).
In contrast to PP2A and PP5, it remained unclear whether PP1α also
regulates GR function. In rat fibroblasts, the subcellular distribution of
the GR was influenced by inhibiting activities of PP1 and PP2A using
okadaic acid, a potent but unspecific inhibitor of PP1
(IC50 = 15–20 nM) and PP2A (IC50 = 0.1 nM) (Bialojan and Takai,
1988; Cohen et al., 1989; DeFranco et al., 1991; Somers and DeFranco,
1992). The PP1 holoenzyme is a serine/threonine-specific phospho-
protein phosphatase consisting of a catalytic subunit (PP1c) and mul-
tiple regulatory subunits. PP1c has four isoforms PP1α, PP1β, and the
splice variants PP1γ1 and PP1γ2, encoded by three different genes
PPP1CA, PPP1CB and PPP1CC. These isoforms share a high level of
sequence homology and are ubiquitously expressed, except of PP1γ2,
which is restricted to the testis (Ceulemans and Bollen, 2004; Cohen,
2002; Moorhead et al., 2007).
The present study evaluated the impact of PP1α on GR function by
performing a reporter gene assay in HEK-293 cells expressing re-
combinant human GRα and PP1α. To investigate the effect of PP1α on
endogenously expressed GR activity, the transcriptional expression of
GC-induced genes was followed after knockdown of PP1α in A549
human lung carcinoma cells. Furthermore, to assess whether PP1α
regulates GR through dephosphorylation of MDM2, as shown for the
related steroid receptors, or by a direct mechanism similarly to PP2A
and PP5, the pathways underlying the PP1α-mediated effect on GR
stimulation were assessed in A549 cells after silencing of PP1α.
2. Materials and methods
2.1. Chemicals and reagents
Cortisol (CAS Nr. 50-23-7) was purchased from Steraloids (Newport,
RI). Inhibitors of JNK (SP600125, CAS Nr. 129-56-6), p38 MAPK
(SB203580, CAS Nr. 152121-47-6), Akt1/2 kinase (CAS Nr. 612847-09-
3), MEK1/2 (PD98059, CAS Nr. 167869-21-8), and GSK-3 (CHIR99021,
CAS Nr. 252917-06-9), as well as the GR antagonist mifepristone (RU-
486, CAS Nr. 84371-65-3) were obtained from Sigma-Aldrich (Buchs
SG, Switzerland). Stock solutions (10 mM) were prepared in dimethyl
sulfoxide (DMSO, CAS Nr. 67-68-5; AppliChem, Darmstadt, Germany).
2.2. Cell culture and treatments
Human embryonic kidney-293 (HEK-293) cells and A549 human
alveolar carcinoma cells were obtained from ATCC (Manassa, VA, USA).
Cell culture media were purchased from Sigma-Aldrich. HEK-293 cells
were cultured in Dulbecco's modified Eagle medium (DMEM) supple-
mented with 10% fetal bovine serum, 4.5 g/L glucose, 100 U/mL pe-
nicillin/streptomycin, 2 mM L-glutamine, 10 mM HEPES, pH 7.4, and
10% MEM non-essential amino acid solution. A549 cells were grown in
Kaighn's Modification of Ham's F-12 medium (F-12K medium) com-
pleted with 10% fetal bovine serum and 100 U/mL penicillin/strepto-
mycin.
Lipofectamine RNAiMax (Thermo Fisher Scientific, Waltham, MA,
USA) was used for small interfering RNA (siRNA) delivery. Cells
(150′000/6-well) were reverse transfected with 100 pmol siRNA
against PP1α and/or 50 pmol siRNA against GSK-3 and 3.75 μL lipo-
fectamine reagent for 64–66 h. The target sequences recognized by the
siRNAs are: mock (negative control siRNA with a randomly selected
non-targeting sequence) 5′-UGGUUUACAUGUUUUCUGA-3′, PPP1CA
(PP1α) 5′-CAAGAGACGCUACAACAUC-3' (both from Microsynth AG,
Balgach, Switzerland); GSK3A (L-003009-00-0005) 5′-UCACAAGCUU
UAACUGAGA-3′, 5′-GAAGGUGACCACAGUCGUA-3′, 5′-GAGUUCAAG
UUCCCUCAGA-3′, 5′-CUGGACCACUGCAAUAUUG-3′ and GSK3B (L-
003010-00-0005) 5′-GAUCAUUUGGUGUGGUAUA-3′, 5′-GCUAGAUCA
CUGUAACAUA-3′, 5′-GUUCCGAAGUUUAGCCUAU-3′, 5′-GCACCAGAG
UUGAUCUUUG-3' (all from Dharmacon ON-TARGET plus SMART
POOL; Dharmacon, Lafayette, CO, USA).
To determine effects of PP1α knockdown on endogenous GC-in-
duced transcripts, A549 cells were cultured in steroid-free medium for
16–18 h prior to incubation with increasing concentrations of cortisol
(18.75 nM–1200 nM) or vehicle (DMSO) for 4 h. To study effects of
kinase inhibitors on PP1α-dependent downregulation of GC-induced
genes, A549 cells were treated with indicated inhibitors (10 μM, except
for GSK-3 inhibitor (5 μM)) in serum-free medium for 16–18 h prior to
incubation with cortisol (500 nM) or vehicle (DMSO) for another 4 h.
Following treatments, total RNA was isolated and quantitative poly-
merase chain reaction performed to quantify GILZ (glucocorticoid-in-
duced leucine zipper), IGFBP1 (insulin-like growth factor binding pro-
tein 1) and SDPR (serum deprivation-response protein).
Cellular fractionation and phosphorylation of GR was assessed by
pre-incubating the cells with steroid-free medium overnight following
treatment of cortisol for another 1 h prior to cell lysis. Cellular frac-
tionation experiments in HEK-293 and A549 cells were performed using
50 nM and 500 nM cortisol, respectively. GR phosphorylation in
A549 cells was analyzed in the presence of 10 nM and 50 nM cortisol. In
all cell treatments, the final concentration of DMSO did not exceed
0.05%.
2.3. GR-dependent reporter gene assay
HEK-293 cells (100'000 cells/well) were seeded in poly-L-lysine
coated 24-well plates, incubated for 24 h and co-transfected by calcium
phosphate precipitation with the reporter gene TAT3-TATA luciferase
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(0.375 μg/well), pCMV-Renilla constitutive luciferase transfection
control (0.03 μg/well) and the indicated plasmids coding for human
GRα, Flag-PP1α and Myc-MDM2 (at a ratio of 1:4:4). Empty vector
pcDNA3.1 was supplemented to equalize the total amount of DNA in
the transfection. After 4 h, cells were washed with phosphate-buffered
saline (PBS) and incubated in DMEM for another 18 h. Cells were then
adapted to charcoal-treated DMEM (cDMEM) for 2 h. Cells were ex-
posed 24 h post-transfection to DMSO control, cortisol (0.1–100 nM) or
mifepristone (RU-486; 1 μM), followed by incubation for another 24 h.
Cells were then lysed in passive lysis buffer (Promega, Madison, WI,
USA) and fire fly and Renilla luciferase activity were determined ac-
cording to the Dual-Luciferase® reporter assay kit (Promega, Madison,
WI, USA) using a SpectraMax-L luminometer (Molecular Devices,
Devon, UK).
2.4. RNA isolation and quantitative polymerase chain reaction (RT-qPCR)
For isolation of total RNA, the RNeasy Mini Kit (QIAGEN, Hilden,
Germany) was applied on a QIAcube extraction robot (QIAGEN) ac-
cording to the manufacturer. The extracted RNA was treated with the
RapidOut DNA Removal Kit (Thermo Fisher Scientific) and com-
plementary DNA (cDNA) was subsequently synthesized using the
GoScript Reverse Transcription System (Promega) following the man-
ufacturer's protocol. RT-qPCR comprising 40 cycles of 95 °C for 10 s,
60 °C for 15 s, followed by a final extension at 72 °C for 20 s, and a
dissociation curve (72 °C–95 °C) was performed in technical triplicate
for each sample in the Rotor-Gene Q (QIAGEN) by using KAPA SYBR
Fast qPCR Master Mix (2X) Kit (KAPA Biosystems, Woburn, MA, USA).
For relative quantification, expression levels were normalized to those
of the endogenous control gene cyclophilin A (CYPA) according to the
comparative 2−ΔCt method (Livak and Schmittgen, 2001). CYPA was
chosen as housekeeping gene since its expression did not alter between
experimental conditions and complied with the quality criteria for re-
ference genes (Taylor et al., 2010). Table 1 shows sequences of oligo-
nucleotide primers.
2.5. Western blot analysis
Upon treatment, cells were washed in PBS and lysed for 30 min on
ice in RIPA buffer (Sigma-Aldrich) containing protease inhibitor cock-
tail (Roche, Rotkreuz, Switzerland). All steps of the lysis process were
performed at 4 °C, which was sufficient to drastically reduce the activity
of phosphatases. An initial experiment showed no effect of phosphatase
inhibitor cocktail (data not shown), therefore it was not added to the
lysis buffer. After centrifugation (16′000 × g, 15 min, 4 °C), the su-
pernatant was analyzed using a Pierce® biocinchonic acid protein assay
kit (Thermo Fisher Scientific). Laemmli solubilization buffer (LSB;
60 mM Tris–HCl, 10% glycerol, 2% (w/v) sodium dodecyl sulfate,
0.01% bromophenol blue, pH 6.8) supplemented with 5% β-mercap-
toethanol (Promega) was added and samples were boiled for 3 min.
Total protein (20 μg) of whole-cell extracts was resolved on 8% or 12%
bis-acrylamide gels by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE). All proteins were transferred to Immun-
Blot® polyvinylidene difluoride (PVDF) membranes (Bio-Rad
Laboratories, Hercules, CA, USA), which were subsequently blocked
with 5% defatted milk in Tris-buffered saline (20 mM Tris buffer (pH
7.6), 150 mM NaCl) containing 0.1% Tween-20 (TBS-T) for 1 h.
Membranes were incubated with the indicated primary antibodies in
blocking solution overnight at 4 °C. After washing with TBS-T, the
membranes were probed with horseradish peroxidase-conjugated goat
anti-mouse secondary antibody (A0168) or goat anti-rabbit secondary
antibody (A0545; both 1:10′000, from Sigma-Aldrich) for 1 h at room
temperature. Visualization and detection of the protein bands was
performed on a Fujifilm ImageQuant™ LAS-4000 (GE Healthcare,
Glattbrugg, Switzerland) using the Immobilon Western
Chemiluminescent HRP substrate kit (Merck, Kenilworth, NJ, USA).
Quantitation of at least two independent experiments was done by
using NIH ImageJ software and densitometry values were corrected for
loading differences by normalization to those of β-actin or CYPA
housekeeping control.
The following primary antibodies were used: Anti-GR antibody
(1:2′000; sc-1003; validated earlier (Mani et al., 2016)), anti-PP1α
antibody (1:5′000; sc-271762), and anti-β-actin antibody (1:10′000; sc-
47778; all from Santa Cruz Biotechnology, Dallas, TX, USA); anti-
pSer134 GR antibody (1:2′000; 85060), anti-pSer211 GR antibody
(1:2′000; 4161; verified earlier (Oakley et al., 2017)), anti-pSer226 GR
antibody (1:10′000; 97285), and anti-GSK-3 antibody (1:5′000; 5676;
all from Cell Signaling Technology, Danvers, MA, USA); anti-pSer203
GR antibody (1:2′000; orb127112; Biorbyt Ltd., Cambridge, United
Kingdom); anti-Flag antibody (1:2′000; MA1-91878; Thermo Fisher
Scientific), anti-pSer404 GR antibody (1:1′000; described earlier
(Galliher-Beckley et al., 2008)), anti-CYPA antibody (1:10′000,
ab41684; Abcam Inc, Cambridge, United Kingdom).
2.6. Cellular fractionation
Treated cells were washed with PBS, scraped from culture dishes on
ice and centrifuged at 500 × g for 5 min at 4 °C. Cell pellets were
resuspended in ice-cold lysis buffer (10 mM HEPES, 1.5 mM MgCl2,
10 mM KCl, pH 7.6) supplemented with protease inhibitor cocktail
(Roche) and 1 mM dithiothreitol (DTT, AppliChem). After incubation
for 15 min, cells were permeabilized with 0.57% IGEPAL CA-630
(Sigma-Aldrich), vortexed vigorously for 10 s and centrifuged at 8′000
× g for 5 min at 4 °C. The supernatant was collected as cytosolic
fraction and clarified by centrifugation (16′000 × g, 5 min, 4 °C) fol-
lowing protein quantification. After removing the cytosolic fraction, the
pellet was washed twice with PBS, centrifuged (800 × g, 5 min, 4 °C)
and the supernatant discarded. The pellet was resuspended in extrac-
tion buffer (20 mM HEPES, 1.5 mM MgCl2, 0.42 M NaCl, 0.2 mM EDTA,
25% (v/v) glycerol, pH 7.9) supplemented with protease inhibitor
cocktail (Roche) and 1 mM DTT for 20 min at 4 °C and 1′400 rotations/
min on an orbital shaker (Thermomixer, Vaudaux-Eppendorf, Buchs,
Switzerland). The homogenate was centrifuged at 21′000 × g for
5 min at 4 °C and the supernatant removed as nuclear fraction, followed
by protein quantification. Nuclear and cytoplasmic fractions were
electrophoretically separated and blotted to PVDF membranes.
Membranes were probed with anti-β-actin or anti-α-tubulin (1:10′000;
GTX628802; GeneTex, Irvine, CA, USA) antibodies as cytoplasmic
markers and anti-HDAC1 antibody (1:5′000; 5356; Cell Signaling
Technology) as nuclear marker.
2.7. Co-immunoprecipitation
For co-immunoprecipitation experiments using Pierce™ NHS-
Activated Agarose Slurry (Thermo Scientific), anti-GR antibody (sc-
1003, Santa Cruz Biotechnology) was immobilized on beads according
to the manufacturer. Cells suspended in lysis buffer (Atanasov et al.,
2008) and proteins (1000 μg) were immunoprecipitated with antibody-
coupled beads overnight at 4 °C. As a control of antigen-antibody
binding specificity, lysates were incubated with rabbit IgG antibody (sc-
2027, Santa Cruz Biotechnology). After elution of the precipitated
protein, Western blot analysis was performed.
Table 1
Sequences of gene-specific primers used for RT-qPCR.
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Co-immunoprecipitation with Pierce™ Protein A/G Plus Agarose
(Thermo Scientific) was performed as described previously (Petrillo
et al., 2019). Briefly, 1000 μg of whole-cell extract proteins were in-
cubated with anti-GR antibody (3660, Cell Signaling Technology) or
anti-PP1α antibody (sc-271762, Santa Cruz Biotechnology) overnight at
4 °C. Rabbit IgG antibody (12–370, Merck, Darmstadt, Germany) or
mouse IgG antibody (sc-2025, Santa Cruz Biotechnology) was used as a
control of non-antigen specific binding. Beads were added to each
sample for another 3 h at 4 °C. The beads were washed twice with Co-IP
buffer (50 mM Tris buffer, pH 7.6, 150 mM NaCl, 1% NP-40, 10%
glycerol, 5 mM MgCl2) containing protease inhibitor cocktail and 1 mM
phenylmethanesulfonyl fluoride (PMSF; AppliChem) and twice with
PBS. After eluting the proteins from the beads by adding LSB supple-
mented with 5% β-mercaptoethanol and heating for 5 min at 99 °C,
they were subjected to Western blot analysis.
2.8. Statistical analysis
Statistical evaluation was conducted in GraphPad Prism version 5.0.
Statistical significance of differences between treatments was calculated
using an unpaired two-tailed Student's t-test, one-way ANOVA followed
by Tukey's multiple comparisons test or two-way ANOVA followed by
Bonferroni's multiple comparisons test to adjust the false discovery rate.
Values represent mean ± SD and levels of significance are: *P < 0.05,
**P < 0.01, ***P < 0.001, ****P < 0.0001.
3. Results
3.1. PP1α stimulates GR activity independently of MDM2
Although PP1α was found to enhance the activity of AR and MR
through a mechanism involving MDM2-dependent control of receptor
protein stability (Liu et al., 2016; Nagarajan et al., 2017), it remained
unclear whether PP1α would stimulate GR activity and if so by which
mechanism. To investigate the effect of PP1α on GR activity, HEK-
293 cells were transiently transfected with human GR, PP1α and a GR-
dependent luciferase reporter gene. An excess of PP1α over GR ex-
pression plasmid of 4:1 optimally stimulated GR-dependent luciferase
reporter activity. Co-transfection with PP1α significantly increased
basal and cortisol-dependent GR activity, by a cortisol concentration-
dependent manner (Fig. 1A). In PP1α-overexpressing cells, the maximal
GR transcriptional activity was observed when cells were treated with
3.7 nM cortisol, resulting in a 7-fold higher GR-mediated luciferase
activity compared with cells expressing GR alone. In the absence of
PP1α, maximal GR activity was detected in the presence of 30 nM
cortisol. PP1α overexpression significantly affected the affinity of GR
for cortisol (EC50 GR = 5.9 ± 2.8 nM; EC50 GR+PP1α = 1.4 ± 0.1 nM;
P value = 0.01). To exclude non-specific effects of PP1α on the pro-
moter, HEK-293 cells transiently expressing GR and PP1α were treated
with the GR antagonist mifepristone (RU-486) in the absence or pre-
sence of cortisol (Suppl. Fig. 1A). As mifepristone is known to exhibit
also some weak agonistic effects (Jewell et al., 1995; Qi et al., 1990;
Zhang et al., 2007), co-expression with PP1α slightly increased the
activity of GR upon incubation with mifepristone. However, in the
presence of cortisol, the pronounced PP1α-dependent activation was
almost completely reversed by co-treatment with mifepristone. Fur-
thermore, in the absence of GR, i.e. in HEK-293 cells transfected with
the GR-dependent luciferase reporter gene and PP1α alone, no sig-
nificant induction of the reporter by PP1α was observed in both the
absence and presence of cortisol (Suppl. Fig. 1B). This indicates that the
PP1α-dependent stimulation is mediated via GR.
Since the effects of PP1α on MR and AR were assumed to be
mediated by inhibition of MDM2-dependent receptor degradation (Liu
et al., 2016; Nagarajan et al., 2017), the impact of MDM2 on GR activity
was assessed in HEK-293 cells expressing the respective recombinant
proteins. Although MDM2 overexpression led to decreased GR-
mediated reporter gene activity, the PP1α-dependent stimulation of GR
transactivation could not be prevented, neither under basal (Fig. 1B)
nor under cortisol-stimulated (Fig. 1C) conditions. In the basal state,
PP1α enhanced the GR transactivation in the absence of MDM2 4.5-fold
and in its presence 4-fold. Similarly, in the presence of 100 nM cortisol
PP1α stimulated GR activity about 2-fold.
Furthermore, to test whether PP1α alters the translocation of cy-
tosolic GR into the nucleus, nuclear and cytosolic fractions of HEK-
293 cells transfected with GR in the absence or presence of PP1α were
analyzed by Western blotting (Fig. 1D and E). As expected, cortisol
treatment induced nuclear translocation of GR; however, PP1α over-
expression significantly enhanced GR translocation by about 3 times
when the cells were treated with cortisol (Fig. 1E).
3.2. PP1α knockdown decreases GR-dependent gene transcription in
A549 cells
In order to support the stimulatory influence of PP1α on GR activity
that was observed in the HEK-293 overexpression model, A549 human
alveolar carcinoma cells endogenously expressing PP1α and GR were
applied. PP1α was downregulated using siRNA, followed by detection
of GR protein by Western blot analysis. PP1α protein was efficiently
down regulated (Fig. 2A and B), but without significantly affecting GR
protein expression (Fig. 2A and C). Next, cytosolic and nuclear fractions
of A549 cells transfected with PP1α siRNA were analyzed by Western
blotting (Fig. 2D and E), whereby no significant alterations of cytosolic
and nuclear GR protein amounts could be detected. PP1α was found to
be mainly located in the nucleus. In contrast, a homogenous distribu-
tion of PP1α between the cytoplasm and the nucleus along with an
increased GR translocation was observed in HEK-293 cells upon over-
expression of PP1α and GR (Fig. 1D and E). This difference to the
A549 cells might be a result of limited availability of GR and PP1α
associated regulatory proteins in HEK-293 cells. Nevertheless, these
data suggest that the PP1α-dependent GR activation is not a cause of
altered receptor protein stability and unlikely mediated through
MDM2.
Furthermore, co-immunoprecipitation assays using A549 cell lysates
were performed according to two different protocols using two anti-
bodies against different epitopes on GR in order to determine whether
PP1α and the GR interact directly. Moreover, pull-down experiments
were conducted once with an antibody against GR (Suppl. Fig. 2A and
2B) and once with an antibody against PP1α (Suppl. Fig. 2C and 2D).
Nevertheless, there was no evidence for a physical interaction between
PP1α and GR, both in the absence (Suppl. Fig. 2A and 2C) and presence
(Suppl. Fig. 2B and 2D) of cortisol.
Importantly, the cortisol-induced expression of the endogenous GR-
responsive genes IGFBP1 and GILZ was markedly downregulated, in a
concentration-dependent manner, in PP1α siRNA transfected cells
compared to mock siRNA transfected cells (Fig. 2F and G). In addition,
using a different PP1α-specific siRNA confirmed the effect of PP1α si-
lencing on the expression of GILZ and IGFBP1 (Suppl. Fig. 3).
3.3. PP1α knockdown results in reduced GR-Ser211 phosphorylation
Since PP1α stimulated the activity of the GR but did not seem to
influence its stability nor directly interact with the receptor, it was next
assessed whether altered phosphorylation at four well-characterized
sites on GR, namely serine residues 134, 203, 211 and 226, may affect
the transcriptional response to GC. For this purpose, A549 cells were
transfected with siRNA against PP1α, treated with 10 nM or 50 nM
cortisol for 1 h, prior to cell lysis, and Western blot analysis using
phospho-specific and total anti-GR antibodies was performed to de-
termine the serine residues influenced (Fig. 3A). Silencing of PP1α did
not affect GR phosphorylation of serine residues 134, 203 and 226
(Suppl. Fig. 4A–C), but reduced the phosphorylation status of Ser211 in
a GC-independent manner (Fig. 3B). Influences on the phosphorylation
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Fig. 1. Effect of PP1α overexpression on GR activity and nuclear translocation. (A, B and C) HEK-293 cells were transiently transfected with plasmids coding for GR
with or without PP1α, a luciferase reporter gene and a Renilla luciferase transfection control. Empty vector pcDNA3.1 was supplemented to equalize the total amount
of DNA in the transfection. After 24 h of transfection, cells were incubated with vehicle or increasing concentrations of cortisol (A) for another 24 h. The luciferase
reporter activity was normalized to the internal Renilla control. (B), under basal conditions, and (C) under cortisol-stimulated conditions as in (A) but with co-
transfection of MDM2. Data represent mean ± SD from at least two independent experiments, each performed in triplicate, ****P < 0.0001, ***P < 0.001,
**P < 0.01, ns not significant. (D and E) HEK-293 cells were transfected with GR, with and without PP1α for 24 h, incubated overnight in charcoal-treated medium
and then exposed to vehicle or 50 nM cortisol for 1 h. Cytosolic and nuclear fractions were analyzed by Western blot using antibodies against GR and the Flag-tag on
PP1α. As controls, the fractions were reprobed with anti-β-actin (cytosolic) and anti-HDAC1 (nuclear) antibodies. A representative blot (D) and analysis of band
density (E) from two independent experiments are shown. Values are depicted as mean ± SD, *P < 0.05, ns not significant.
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Fig. 2. Impact of PP1α knockdown on endogenous GR protein expression, translocation and GC-induced transcripts. (A, B and C) Western blot analysis for protein
expression of GR and PP1α was performed after mock or anti-PP1α siRNA treatment in A549 cells. A representative blot (A) and densitometry analysis of PP1α (B)
and GR (C) from three independent experiments are shown. Data are normalized to mock siRNA samples (mean ± SD, ****P < 0.0001, ns not significant). (D and
E) A549 cells were transfected with mock or anti-PP1α siRNA for 48 h, incubated overnight in serum-free medium and treated with vehicle or 500 nM cortisol for 1 h.
Western blot analysis for cytosolic and nuclear fractions was performed using antibodies against GR and PP1α. As controls, the fractions were reprobed with anti-α-
tubulin (cytosolic) and anti-HDAC1 (nuclear) antibodies. A representative blot (D) and analysis of band density (E) from two independent experiments are shown.
Values are presented as mean ± SD, ns not significant. (F and G) At 48 h after knockdown of PP1α, A549 cells were cultured in steroid-free medium overnight prior
to incubation with vehicle or increasing concentrations of cortisol (18.75 nM–1200 nM) for 4 h. Cortisol-induced transcription of the GR-responsive genes IGFBP1 (F)
and GILZ (G) was measured by RT-qPCR in technical triplicate for each sample. Data are represented as 2−ΔCt mean ± SD from three independent experiments,
****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05, ns not significant.
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of Ser404 were also tested. The antibody signal for GR-Ser404 was very
weak and several other bands were detected, not allowing densitometry
analysis; however, there was no evidence supporting altered phos-
phorylation upon PP1α knockdown (data not shown).
3.4. Impact of various kinase inhibitors on the PP1α-mediated effect on GR-
induced transcripts
Next, in an attempt to start to understand the mechanism under-
lying the influence of PP1α on GR-Ser211 phosphorylation, A549 cells
transfected with mock or anti-PP1α siRNA were exposed to inhibitors of
several known kinases. The mRNA expression levels of the two GR-re-
sponsive genes IGFBP1 and GILZ were then measured in order to
identify the kinase(s) involved in the PP1α-dependent GR stimulation.
In both, the basal and cortisol-activated state, a significant decrease in
the GILZ and IGFBP1 mRNA expression was observed in cells trans-
fected with siRNA against PP1α compared to mock siRNA treated cells
(Fig. 4A–D). This effect of PP1α knockdown was retained when the cells
were exposed to inhibitors of p38, MEK1/2, JNK and Akt1/2. In con-
trast, the PP1α-mediated effect on both genes was reversed by treat-
ment with the GSK-3 inhibitor, i.e. expression levels in mock treated
cells were reduced to those of cells transfected with anti-PP1α siRNA,
indicating an involvement of GSK-3 in the PP1α-dependent GR stimu-
lation. However, IGFBP1 expression was abrogated in the presence of
GSK-3 inhibitor. IGFBP1 carries a thymine-rich insulin response ele-
ment (TIRE) in its promoter region (Finlay et al., 2004), implying that
GSK-3 has to be active for efficient gene transcription. Therefore,
IGFBP1 is not appropriate to demonstrate the impact of GSK-3 on the
PP1α-mediated GR activation, and another GR-dependent gene, SDPR,
was analyzed under both basal and cortisol-stimulated conditions
(Fig. 4E and F). The results support an involvement of GSK-3 in the
PP1α-related GR modulation (see Fig. 6 for an overview of the proposed
mechanism). It needs to be noted that, when comparing mock trans-
fected cells incubated with DMSO or cortisol vs inhibitors, p38 and
MEK1/2 inhibitors did not exert a pronounced effect on GILZ and
IGFBP1 gene expression levels, whereas JNK and Akt1/2 inhibitors
markedly increased the expression levels of these genes in both basal
and cortisol-stimulated state. This suggests that JNK and Akt1/2 path-
ways are active in A549 cells and their inhibitors influenced GILZ and
IGFBP1 expression independent of PP1α.
3.5. Inhibition or knockdown of GSK-3 abrogates the PP1α-dependent effect
on GR-Ser211 phosphorylation
To assess whether pharmacological inhibition of GSK-3 can di-
minish the PP1α-dependent effect on GR-Ser211 phosphorylation,
A549 cells were treated with GSK-3 inhibitor, followed by Western blot
analysis. Upon cortisol stimulation in mock siRNA transfected cells,
GSK-3 inhibition significantly decreased GR-Ser211 phosphorylation,
reducing the phosphorylation level to that observed in the absence of
PP1α, i.e. in anti-PP1α siRNA treated cells (Fig. 5A and B), suggesting
that GSK-3 mediates the PP1α-dependent activation of GR. To further
support a role for GSK-3 and exclude an off-target effect of the GSK-3
kinase inhibitor as well as to examine the involved GSK-3 isoform,
isoform-specific anti-GSK-3 siRNAs were applied under cortisol-stimu-
lated conditions (Fig. 5C and D). Whereas silencing of either GSK-3α or
GSK-3β both only partially reversed the effect of PP1α knockdown on
Ser211 phosphorylation, the combination of both siRNAs fully pre-
vented it. These results imply that GSK-3 inhibition could prevent the
effect of PP1α on Ser211 phosphorylation (see Fig. 6 for an overview of
the proposed mechanism).
4. Discussion
The cell- and tissue-specific sensitivity towards GC plays a pivotal
role in the fine-tuned regulation of physiological functions as well as for
the response to pharmacological doses in the treatment of pathological
conditions. Phosphorylation at multiple sites belongs to the most im-
portant mechanisms allowing a rapid modulation of the sensitivity of
the GR towards GC. The basal and ligand-stimulated phosphorylation of
the GR is regulated by various kinases and phosphatases, and an im-
paired phosphorylation can result in hypersensitivity or resistance to
GC, thereby contributing to diseases (Bouazza et al., 2012; DeFranco
et al., 1991; Galliher-Beckley et al., 2008, 2011; Habib et al., 2017; Itoh
Fig. 3. Effect of PP1α knockdown on GR phosphorylation. A549 cells were transfected with mock or anti-PP1α siRNA for 48 h, incubated in serum-free medium for
16–18 h, treated with vehicle or cortisol (10 nM and 50 nM cortisol) for 1 h, followed by cell lysis and Western blot analysis. A representative Western blot image (A)
and densitometry values (B) are presented. Levels of phosphorylated Ser211 from three independent experiments were normalized to total GR levels and are depicted
as values normalized to mock siRNA control (mean ± SD, ***P < 0.001, **P < 0.01, ns not significant).
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et al., 2002; Kino et al., 2007; Kobayashi et al., 2011; Krstic et al., 1997;
Miller et al., 2005; Pazdrak et al., 2016; Rogatsky et al., 1998a;
Rogatsky et al., 1998; Webster et al., 1997; ).
PP1α is a ubiquitously expressed protein phosphatase that regulates
a vast variety of cellular processes by dephosphorylation of serine/
threonine-phosphorylated protein substrates, including cell cycle pro-
gression, protein synthesis, mRNA splicing and transcription, calcium
signaling and carbohydrate metabolism (Ceulemans and Bollen, 2004;
Fig. 4. Effect of various kinase inhibitors on the PP1α-dependent effect on GR-induced transcripts. A549 cells were transfected with mock or anti-PP1α siRNA for
48 h, incubated overnight with indicated inhibitors (10 μM; except for GSK-3 inhibitor, 5 μM) in serum-free medium prior to further incubation with vehicle (A, C and
E) or 500 nM cortisol (B, D and F) for another 4 h. Expression levels of GR-responsive genes IGFBP1 (A and B), GILZ (C and D) and SDPR (E and F) were analyzed by
RT-qPCR. Values are relative to those of the endogenous control gene using the comparative 2−ΔCt method, followed by normalization to mock siRNA samples. Data
are presented as mean ± SD from three independent experiments, each performed in technical triplicate. **P < 0.01, *P < 0.05, ns not significant.
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Cohen, 2002). Despite its multiple functions, the impact of PP1α on the
modulation of GR activity has not yet been investigated. The current
study assessed whether PP1α can stimulate GR function and tested two
different hypotheses: First, that PP1α regulates GR activity through
suppression of MDM2 activity by dephosphorylating it at Ser166,
thereby reducing the MDM2-mediated ubiquitination of GR and the
subsequent proteasomal degradation of the receptor, as shown for the
MR and AR (Liu et al., 2016; Nagarajan et al., 2017); and second, that
PP1α directly dephosphorylates the GR at a particular site to relieve
functional repression as demonstrated for PP2A and PP5 (Bouazza
et al., 2012; Kobayashi et al., 2011; Pazdrak et al., 2016).
The results revealed a stimulating effect of PP1α on GR activity in
HEK-293 cells overexpressing recombinant proteins and a GR-depen-
dent luciferase reporter (Fig. 1A), as well as in A549 cells expressing
endogenous GR and PP1α levels by PP1α silencing and assessment of
the expression of the GC-target genes IGFBP1 and GILZ (Fig. 2F and G).
In addition, PP1α overexpression seems to enhance the affinity of GR to
cortisol (Fig. 1A). In the absence of ligand, only few receptor molecules
exist in the active conformation. The GR might adopt a low affinity
antagonist state wherein helix 12 occupies a position covering the
coactivator binding site and in which the steroid binding pocket re-
mains closed (Frego and Davidson, 2006; Hu et al., 2011; Kauppi et al.,
2003; Quax et al., 2013). Upon ligand binding, the number of receptors
in the active conformation increases, indicating that the position of
helix 12 enables interaction with coactivator proteins and consists of an
open ligand binding pocket. Co-expression with PP1α might further
augment the number of receptors in the active conformation, indirectly
by promoting phosphorylation of Ser211, leading to increased ligand
binding and a shift to higher affinity.
MDM2 has been shown to control the expression of several steroid
receptors including the GR (Sengupta and Wasylyk, 2001). In line with
previous observations, co-transfection with MDM2 in HEK-293 cells
was found to decrease GR transcriptional activity, both in the basal and
cortisol-activated state. However, MDM2 overexpression could not
Fig. 5. Effect of GSK-3 on the PP1α-mediated impact on GR-Ser211 phosphorylation. (A and B) After treatment with mock or anti-PP1α siRNA, A549 cells were
incubated overnight with 5 μM GSK-3 inhibitor in serum-free medium prior to further incubation with vehicle or 50 nM cortisol for another 1 h. Western blot analysis
for expression of total GR protein and Ser211 phosphorylation was performed. A representative blot (A) and densitometry values of Ser211 phosphorylation (B) from
two independent experiments normalized to total GR are shown. (C and D) A549 cells were co-transfected with siRNA against PP1α and/or GSK-3α and/or GSK-3β
for 48 h, incubated overnight in serum-free medium prior to treatment with 50 nM cortisol for another 1 h. Western blotting for expression of total GR protein and
Ser211 phosphorylation was conducted. A representative blot (C) and densitometry analysis of Ser211 phosphorylation (D) from three independent experiments
normalized to total GR is presented as values normalized to mock siRNA control. Data represent mean ± SD, **P < 0.01, *P < 0.05, ns not significant.
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prevent the PP1α-mediated GR activation, with similar relative in-
creases of GR activity in the absence or presence of MDM2. This in-
dicates that PP1α stimulates GR activity by an MDM2-independent
mechanism. Moreover, knockdown of PP1α in A549 cells revealed re-
duced GR-dependent gene expression but did not result in decreased GR
protein expression levels, further supporting that PP1α-dependent GR
stimulation is independent of MDM2 modulated receptor stability and
differs from the mechanism observed for MR and AR (Liu et al., 2016;
Nagarajan et al., 2017).
Furthermore, proximity ligation assays suggested an interaction
between PP1α and MR, and immunoprecipitation analysis indicated
that PP1α interacts with the LBD of the AR (Liu et al., 2016; Nagarajan
et al., 2017). In this study, co-immunoprecipitation assays failed to
detect a direct interaction between GR and PP1α, further favoring a
different mechanism compared to MR and AR. Nevertheless, methods to
detect weak and transient interactions such as proximity ligation assays
should be performed in follow-on experiments.
To achieve its transcriptional activity, the GR has to translocate
from the cytoplasm into the nucleus. Analysis of nuclear and cytosolic
fractions of HEK-293 cells overexpressing recombinant GR and PP1α
revealed a slight but significantly enhanced cortisol-induced GR
translocation from the cytoplasm to the nucleus in the presence of PP1α
(Fig. 1D and E). In contrast, the amount of GR in the nuclear fraction
was not affected by PP1α silencing in A549 cells expressing endogenous
receptor levels (Fig. 2D and E). This difference in the nuclear import of
the GR between the two cell lines might derive from the presence or
absence of receptor-associated co-regulators. Furthermore, it should be
noted that while the overexpressed PP1α in HEK-293 cells shows an
equal distribution between cytoplasm and nucleus, endogenous PP1α in
A549 cells is mainly located in the nucleus. This suggests that sub-
cellular localization less likely is a major factor contributing to the
PP1α-dependent GR activation.
The site-specific phosphorylation of GR regulates its transcriptional
activity (Galliher-Beckley and Cidlowski, 2009; Zhou and Cidlowski,
2005). Earlier studies reported that phosphorylation of GR-Ser211 en-
hances the activity of the receptor, whereas phosphorylation of serine
residues 134, 203, 226 and 404 is associated with reduced GR function
(Chen et al., 2008; Galliher-Beckley et al., 2008, 2011; Habib et al.,
2017; Kino et al., 2007; Krstic et al., 1997; Miller et al., 2005, 2007;
Rogatsky et al., 1998a,b; Takabe et al., 2008; Wang et al., 2002). Thus,
this study explored whether PP1α-dependent GR stimulation was due to
an altered phosphorylation of GR at specific serine residues known to be
Fig. 6. Schematic representation of the modulation of GR activity by PP1α and GSK-3. (A) Upon entering the cell, cortisol binds to GR and leads to receptor
dimerization. For gaining full activity, GR is phosphorylated at Ser211 to activate the transcription of target genes such as IGFBP1, GILZ and SDPR. Phosphorylation
of Ser211 is mediated, at least in part, by a mechanism involving active GSK-3. PP1α dephosphorylates and activates GSK-3. (B) Knockdown of PP1α prevents GSK-3
activation, and inhibition as well as knockdown of GSK-3 diminishes GR-Ser211 phosphorylation, its activation and stimulation of target gene transcription.
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critical for its activity. The data obtained demonstrated that the level of
GR-Ser211 phosphorylation significantly decreased after PP1α silen-
cing (Fig. 3A and B) whereas all other phosphorylation sites tested were
unaffected (Suppl. Fig. 4). Since phosphorylation of GR-Ser211 is es-
sential for receptor activity, a reduced phosphorylation of this specific
residue implicates a decreased transcriptional activity, which was
supported by the diminished expression of GC-inducible genes in
A549 cells upon PP1α knockdown (Fig. 2F and G). The involvement of
GR-Ser211 phosphorylation supports the assumption that altered sub-
cellular trafficking is a mechanism less likely contributing to the PP1α-
dependent GR activation. Earlier findings have shown that mutation of
murine GR at Ser220, the phosphorylation site corresponding to human
Ser211, did not affect hormone-dependent nuclear translocation
(Webster et al., 1997). The fact that PP1α altered the phosphorylation
state of GR-Ser211, and bearing in mind that PP1α is a protein phos-
phatase, indicates an indirect effect of PP1α on GR, involving another
protein.
The present study addressed whether PP1α might dephosphorylate
a specific kinase, which in turn is activated, thereby phosphorylating
GR at Ser211. Treatment of A549 cells with different inhibitors of
known kinases indicated an involvement of GSK-3 in the PP1α-depen-
dent regulation of GC-responsive genes (Fig. 4). Interestingly, inhibitors
of JNK and Akt1/2 markedly enhanced mRNA expression levels of GILZ
and IGFBP1. JNK was postulated to promote the nuclear export of GR
accompanied by termination of GR-dependent transcription through
phosphorylation of GR-Ser226 (Itoh et al., 2002), whereas Akt1 was
found to delay GR nuclear translocation and reduce GR transcriptional
activity by phosphorylation of GR at Ser134 (Habib et al., 2017).
Consequently, inhibition of these kinases may result in a decrease in the
inhibitory phosphorylation of GR-Ser226 and GR-Ser134, respectively,
ultimately leading to increased GR-dependent transcription, as ob-
served in Fig. 4A–D.
Inhibition of GSK-3 prevented the PP1α-mediated difference in the
expression levels of GILZ and SDPR as well as completely abolished the
effects on IGFBP1. IGFBP1 contains a thymine-rich insulin response
element (TIRE) in its promoter region which requires GSK-3 to be active
for gene transcription (Finlay et al., 2004), providing an explanation for
the repression of IGFBP1 gene expression upon treatment of cells with
GSK-3 inhibitor. To assess the role of GSK-3 in the PP1α-dependent
effect on GR function, Western blot analysis was performed to de-
termine GR-Ser211 phosphorylation levels. Treatment of A549 cells
with GSK-3 inhibitor (Fig. 5A and B) and siRNA against GSK-3α/β
(Fig. 5C and D) resulted in a diminished GR-Ser211 phosphorylation
and an abrogated PP1α-mediated effect. Specific knockdown of either
GSK-3α or GSK-3β partially abolished the PP1α-dependent effect,
suggesting that the isoforms might compensate for each other and both
are involved in the stimulatory effects of PP1α on GR activity.
GSK-3 is a serine/threonine protein kinase encoded by two genes
GSK3A and GSK3B. The closely related isoforms α and β are highly
homologous in their catalytic domains but differ significantly in the N-
and C-terminal regions (Woodgett, 1990, 1991), suggesting that they
could be differentially regulated. However, both proteins are similarly
modified at the N-terminal region: phosphorylation of Ser21 on GSK-3α
and Ser9 on GSK-3β (Sutherland et al., 1993; Sutherland and Cohen,
1994). PP1α is a known activator of GSK-3β by dephosphorylation of
Ser9 (Morfini et al., 2004; Szatmari et al., 2005), and was shown to be
engaged in a positive feedback loop with its inhibitor-2 and GSK-3β.
GSK-3β can phosphorylate inhibitor-2 of PP1α at Thr72, resulting in
PP1α activation, which in turn dephosphorylates and further stimulates
GSK-3β (Szatmari et al., 2005; Zhang et al., 2003). It is also assumed
that PP1α can dephosphorylate the inhibitory Ser21 on GSK-3α
(Spokoini et al., 2010; Zhang et al., 2003). GSK-3 was originally iden-
tified as a protein capable of regulating glycogen synthase in order to
inhibit glycogen synthesis (Embi et al., 1980) and since then has been
described to phosphorylate a wide variety of substrates that are in-
volved in many cellular processes, including glucose metabolism, cell
differentiation and apoptosis (Ali et al., 2001; Forde and Dale, 2007;
Soutar et al., 2010). In addition, GSK-3 was found to interact with the
GR. In the absence of a ligand, GSK-3α is supposed to be sequestered to
the GR and dissociates from it upon exposure to GC (Spokoini et al.,
2010). So far, most studies focused on the β-isoform of GSK-3. Inhibi-
tion of GSK-3β was reported to suppress GR reporter gene activity and
reduce mRNA expression levels of GILZ, implying that GSK-3β has a
positive role in GR stimulation (Rubio-Patiño et al., 2012). However,
GSK-3β was also proposed to phosphorylate GR-Ser404 and thereby
decreasing its function (Galliher-Beckley et al., 2008). Further studies
are required to clarify the role of GSK-3 in GR regulation, considering
cell type-specific differences. Furthermore, most of the GSK-3 substrates
need to be primed by pre-phosphorylation at a specific serine-proline
site prior to recognition by GSK-3 (Harwood, 2001). Up to now, such a
priming site for GSK-3 within the GR has not been described. Signaling
pathways are complex involving a number of components that can
cross-talk with other signal transduction pathways. Further research
needs to address whether GSK-3 is directly responsible for the PP1α-
dependent phosphorylation of GR-Ser211 or whether the observed ef-
fect is mediated indirectly through another coregulator. Additionally, it
cannot be excluded that GSK-3 dephosphorylation by PP1α is indirect
and mediated by a PP1α regulatory protein.
Moreover, the physiological relevance of PP1α-mediated GR sig-
naling needs to be examined. PP1α has been reported to be involved in
the progression of several disease states, including memory loss, type II
diabetes and cancer (Figueiredo et al., 2014; Ladha et al., 2010; Shastry
et al., 2016). PP1α is assumed to suppress learning and memory and
acts as a potential mediator of cognitive decline during aging (Genoux
et al., 2002). Excessive GSK-3 activity has been associated with neu-
rodegenerative and psychiatric disorders, and GSK-3 inhibitors as well
as GR antagonists are discussed as new potential treatments of Alz-
heimer's disease (Canet et al., 2019; Martinez and Perez, 2008;
Muyllaert et al., 2008). In addition, aberrant GC action and excessive
activity of GSK-3 have been linked with obesity and type II diabetes
(Henriksen and Dokken, 2006; Rose et al., 2010), and regulatory sub-
units of PP1 have been associated with insulin resistance (Ragolia and
Begum, 1998; Xia et al., 1998). Finally, chronic GC treatment can lead
to reduced sensitivity or even resistance in specific cell-types or tissues
and underlying mechanisms have been mainly attributed to the im-
paired GR signaling pathway (Barnes, 2010; Yang et al., 2012). Due to
the ability of PP1α to enhance GR activity, one could speculate that
cells with impaired PP1α function may have an altered response to GC.
Further elucidation of post-translational modification of GR is essential
to understand mechanisms of aberrant GC action potentially leading to
GC insensitivity.
In this study, PP1α was identified as novel regulator of GR, en-
hancing its activity but not affecting the expression of the receptor, both
under basal and ligand-dependent conditions. Furthermore, the results
provided a first insight into the molecular mechanism, proposing GR-
Ser211 to be modulated through involvement of GSK-3 (Fig. 6). Thus,
PP1α constitutes a new component of the GR signaling pathway, sug-
gesting that impaired activity of PP1α in specific situations could alter
GC action and contribute to diseases.
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